Microbial changes in stool, saliva, serum, and urine before and after anti-TNF-α therapy in patients with inflammatory bowel diseases

Yong Eun Park, Hye Su Moon, Dongeun Yong, Hochan Seo, Jinho Yang, Tae Seop Shin, Yoon Keun Kim, Jin Ran Kim, Yoo Na Lee, Young Ho Kim, Joo Sung Kim, Jae Hee Cheon

Research output: Contribution to journalArticlepeer-review

Abstract

Inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis, are chronic immune-mediated intestinal inflammatory disorders associated with microbial dysbiosis at multiple sites, particularly the gut. Anti-tumor necrosis factor-α (TNF-α) agents are important treatments for IBD. We investigated whether microbiome changes at multiple sites can predict the effectiveness of such treatment in IBD. Stool, saliva, serum, and urine biosamples were collected from 19 IBD patients before (V1) and 3 months after (V2) anti-TNF-α treatment, and 19 healthy subjects (control). Microbiota analysis was performed using extracellular vesicles (EVs; all four sample types) and next-generation sequencing (NGS; stool and saliva). The stool, using NGS analysis, was the only sample type in which α-diversity differed significantly between the IBD and control groups at V1 and V2. Relative to non-responders, responders to anti-TNF-α treatment had significantly higher levels of Firmicutes (phylum), Clostridia (class), and Ruminococcaceae (family) in V1 stool, and Prevotella in V1 saliva. Non-responders had significantly higher V2 serum and urine levels of Lachnospiraceae than responders. Finally, Acidovorax caeni was detected in all V1 sample types in responders, but was not detected in non-responders. Microbiome changes at multiple sites may predict the effectiveness of anti-TNF-α treatment in IBD, warranting further research.

Original languageEnglish
Article number6359
JournalScientific reports
Volume12
Issue number1
DOIs
Publication statusPublished - 2022 Dec

Bibliographical note

Funding Information:
This work was supported by funding from Eisai Korea Inc.; and the Korean Association for the Study of Intestinal Diseases [Woo-duk research fee, April 2019]. Professional medical editing was provided by Katherine A. Lyseng-Williamson, Content Ed Net, with funding from Eisai Korea Inc.

Publisher Copyright:
© 2022, The Author(s).

All Science Journal Classification (ASJC) codes

  • General

Fingerprint

Dive into the research topics of 'Microbial changes in stool, saliva, serum, and urine before and after anti-TNF-α therapy in patients with inflammatory bowel diseases'. Together they form a unique fingerprint.

Cite this